Background {#Sec1}
==========

Surfactants are amphipathic molecules with surface activities to reduce surface tensions. They are widely utilized as detergents, solubilizers or emulsifying agents in many industrial fields such as petroleum, food, pharmaceutical and agricultural industries \[[@CR1], [@CR2]\]. The total worldwide production of surfactants is estimated to be over 15 million tons per year, and expected to increase to over 24 million tons annually by 2020 \[[@CR3]\]. Currently, surfactants are mainly derived from petroleum products chemically due to the low cost of production. However, synthetic surfactants are non-biodegradable, which may lead to environmental problems. Therefore, biosurfactants produced by microbial fermentation can be used to replace synthetic surfactants as environmental friendly alternatives \[[@CR4]--[@CR6]\]. The most attractive characteristic of biosurfactant is that they are easily biodegradable and cause less toxic impact to the environment, while having similar properties to synthetic surfactants. Some biosurfactants are also tolerant to a wide range of extreme conditions (low and high pH, high temperature and high salinity) that are frequently encountered in industrial processes, as well as several interesting biological properties like antimicrobial activity \[[@CR2], [@CR7]\]. Biosurfactants can be classified into several categories including glycolipids (rhamnolipids, sophorolipids, trehalose lipids), lipopeptide (surfactin, iturin) and polymeric compounds (emulsan, alasan) \[[@CR9]\]. Among them, rhamnolipids are the most extensively studied because of their excellent physicochemical properties and ability to reach high fermentation titers. Here we focus on reviewing the challenges and opportunities in microbial production of rhamnolipids, as well as potential strategies to address these challenges.

Rhamnolipids {#Sec2}
============

Rhamnolipids are glycolipids containing a hydrophilic group, consisting of either one or two ([l]{.smallcaps})-rhamnose molecules, with a glycosidic linkage to the hydrophobic group made up of one or two β-hydroxy fatty acids (Fig. [1](#Fig1){ref-type="fig"}). Microbial fermentation produces a diversity of rhamnolipid congeners with variations in the chain length, degree of unsaturation for the fatty acid chains, and differences in the number of rhamnose molecules. Rhamnolipids containing one and two rhamnose molecules are known as mono-rhamnolipids and di-rhamnolipids, respectively (Fig. [1](#Fig1){ref-type="fig"}). It is estimated that approximately 60 rhamnolipid congeners and homologues exist in the fermentation broth, while the predominant rhamnolipid species and the concentrations of the congeners are dependent on the rhamnolipid-producing strains \[[@CR8]\]. The physicochemical properties of the rhamnolipids can be greatly affected even with small changes in the composition of the congeners. For instance, the critical micelle concentration (CMC) is about 230 mg/l for rhamnolipid mixture with high proportion of congeners containing unsaturated fatty acids \[[@CR9]\], 5 mg/l for di-rhamnolipids with C~10~ fatty acids, and 40 mg/l for mono-rhamnolipids with C~10~ fatty acids \[[@CR2], [@CR10]\].Fig. 1Rhamnolipid production in *Pseudomonas*. The synthesis pathway for rhamnolipids is indicated while the details for metabolic pathway of glucose and synthesis of Acyl-CoA are not provided. RhlA, RhlB and RhlC are three enzymes essential for rhamnolipid synthesis

Rhamnolipid applications {#Sec3}
------------------------

Rhamnolipids can be widely applied to many industrial fields such as petroleum, bioremediation, agriculture, cosmetics, food processing and pharmaceuticals because of their excellent surface activities and biological activities \[[@CR11], [@CR12]\]. Particularly, rhamnolipids can be used in manufacturing fine chemicals and surface coatings, as food additives and as biological control agents \[[@CR6]\]. The applications have been described in detail in several reviews \[[@CR13]\] and are summarized in Table [1](#Tab1){ref-type="table"}.Table 1Applications of rhamnolipidsApplicationsExamplesReferencesOil recoveryMicrobial enhanced oil recovery (MEOR)\
Increase amount of recoverable oil aided by rhamnolipid-producing microorganisms\[[@CR73]\]\
\[[@CR2], [@CR74]\]BioremediationBioremediation of petroleum at contaminated sites\
Addition of rhamnolipids improves solubility of hydrocarbons to facilitate degradation\[[@CR46], [@CR75]--[@CR78]\]Bioremediation of heavy metal at contaminated lands or in water treatment plant; rhamnolipids can be applied in foaming-surfactant technology to remove heavy metal contaminants\[[@CR2], [@CR11], [@CR79]\]Bioremediation of pesticides at agricultural fields; addition of rhamnolipids can enhance degradation of chemical pesticides\[[@CR11], [@CR79]\]Pest controlAs emulsifier, spreaders and dispersing agent in pesticide formulations\[[@CR2], [@CR79]\]As bio-pesticide against agricultural pests; rhamnolipids have insecticidal activity against green peach aphids and *Aedes aegypti* larvae\[[@CR43], [@CR80]\]Crop protectionAs biocontrol agent against several phytopathogenic fungi; addition of rhamnolipids or rhamnolipid-containing cell-free broth are effective in inhibiting growth of phytopathogens, e.g. *F. oxysporum*, *B. cinerea*, *Mucor* spp. and many more\[[@CR1], [@CR7], [@CR81]--[@CR84]\]As stimulant for plant immunity; induced genes involved in plant's defense system in tobacco, wheat and *Arabidopsis thaliana*; induced biosynthesis of plant hormones important for signaling pathways involved in plant immunity\[[@CR43]\]Food processingAs food ingredients or additives functioning as emulsifier, solubilizer, foaming and wetting agent\[[@CR7]\]As antimicrobial agent preventing food spoilage and for sanitization; rhamnolipids inhibit growth of foodborne pathogenic bacteria, e.g. *L. monocytogenes*, *B. subtilis*; rhamnolipids also prevent formation of biofilms due to their anti-adhesive nature\[[@CR1], [@CR85], [@CR86]\]As a source of ([l]{.smallcaps})-rhamnose; enzymatic hydrolysis of rhamnolipids to obtain ([l]{.smallcaps})-rhamnose, a raw material for production of flavor compounds\[[@CR42], [@CR87]\]Medical useAs biofilm control agent to prevent medical device-related infections; inhibit biofilm formation; synergistic effect with caprylic acid to inhibit biofilms of more resistant pathogens, e.g. *P. aeruginosa* and *S. aureus*\[[@CR2], [@CR88], [@CR89]\]As anticancer agent; rhamnolipids inhibit growth of many human cancer cell lines, e.g. HI-60, BV-173, SKW-3, JMSU-1 and Hela cells\[[@CR2], [@CR19]\]Protein foldingAid in folding of outer membrane protein A\[[@CR90]\]Microbial fuel cellsImprove power density output of microbial fuel cells\[[@CR91]\]Synthesis of nanoparticlesAs structure-directing agent in nanoparticle synthesis\[[@CR92]\]

Rhamnolipid-producing strains {#Sec4}
-----------------------------

Rhamnolipids are thought to be produced by hydrocarbon-degrading microorganisms as the amphipathic characteristics of rhamnolipids are essential for bacteria to uptake and utilize the hydrophobic hydrocarbons as the carbon source \[[@CR14]\]. Some microorganisms produce rhamnolipids only when hydrocarbons are used as the carbon source \[[@CR15]\]. Some rhamnolipid-producing strains can cause nosocomial infections, especially in individuals with reduced immunity because rhamnolipids may be important for the pathogenic effects \[[@CR5]\]. Quite a few rhamnolipid-producing strains have been isolated and characterized (Table [2](#Tab2){ref-type="table"}). Among the available strains, the rhamnolipid yield of *P. aeruginosa* is still the highest.Table 2Isolated rhamnolipid-producing strainsStrainCarbon sourceMaximum yield (g/l)References*Pseudomonas aeruginosa* PAO12.5% (w/v) sunflower oil36.7\[[@CR93]\]*Pseudomonas aeruginosa* Z413% (v/v) waste frying oil9\[[@CR94]\]*Pseudomonas aeruginosa* ATCC 90270.5% (w/v) glucose13.3--46.8 (rhamnose equivalents)\[[@CR95]\]*Pseudomonas aeruginosa* O-2-28% (w/v) soybean oil + 2, 4 and 4% (w/v) after 24 h, 48 h and 72 h respectively70.56\[[@CR65]\]*Pseudomonas chlororaphis* NRRL B-307612% (w/v) glucose1\[[@CR96]\]*Pseudomonas fluorescens* HW-61.5% (w/v) hexadecane1.4--2\[[@CR97]\]*Pseudomonas fluorescens* Migula 18952% (v/v) olive oil2\[[@CR98]\]*Pseudomonas indica* MTCC 37144% (w/v) combination of rice bran, de-oiled rice bran and glucose9.6\[[@CR99]\]*Pseudomonas luteola* B175% (*w/v*) molasses0.53\[[@CR100]\]*Pseudomonas nitroreducens*4% (w/v) glucose5.46\[[@CR101]\]*Pseudomonas putida* B125% (w/v) molasses0.52\[[@CR100]\]*Pseudomonas putida* 21BN2% (w/v) glucose1.2 (rhamnose equivalents)\[[@CR102]\]*Pseudomonas putida* BD22% (w/v) glucose0.15\[[@CR103]\]*Pseudomonas stutzeri*1% (w/v) mannitol + 1% (w/v) coal8.74 (rhamnose equivalents)\[[@CR104]\]*Burkholderia glumae*2% (w/v) canola oil1.007\[[@CR105]\]*Burkholderia kururiensis* KP23^T^3% (w/v) glycerol0.78\[[@CR48]\]*Burkholderia plantarii* DSM 9509^T^1% (w/v) glucose0.04574\[[@CR106]\]*Burkholderia pseudomallei* NCTC 102744% (v/v) glycerolNA\[[@CR107]\]*Burkholderia thailandensis* E2644% (v/v) canola oil1.473\[[@CR108]\]4% (v/v) glycerol2.79\[[@CR109]\]*Acinetobacter* sp. YC-X 20.186% (w/v) *n*-hexadecane1.15\[[@CR110]\]*Acinetobacter calcoaceticus* NRRL B-591901% (v/v) glycerol2\[[@CR12], [@CR111]\]2% (w/v) sodium citrate1.2\[[@CR12]\]*Acinetobacter calcoaceticus* NRRL B-591911% (v/v) glycerol2.2\[[@CR111]\]*Enterobacter asburiae* NRRL B-591891% (v/v) glycerol2\[[@CR111]\]2% (w/v) sodium citrate0.51\[[@CR12]\]*Enterobacter hormaechei* NRRL B-591851% (v/v) glycerol2.4\[[@CR111]\]*Nocardioides* sp. A-82% (w/v) *n*-paraffinNA\[[@CR112]\]*Pantoea stewartii*1% (v/v) glycerol2.2\[[@CR111]\]*Pseudoxanthomonas* sp. PNK-042% (w/v) mannitol0.28\[[@CR113]\]*Renibacterium salmoninarum* 27BN2% (w/v) *n*-hexadecane0.8 (rhamnose equivalents)\[[@CR114]\]*Serriatia rubidaea* SNAU022.931% (w/v) mannitolNA\[[@CR33]\]*Streptomyces* sp. ISP2-49E0.4% (w/v) glucoseNA\[[@CR115]\]*Tetragenococcus koreensis* sp. nov.1% (w/v) glucose + 1% (w/v) sodium acetateNA\[[@CR116]\]*Thermus aquaticus* CCM 34880.2% (w/v) sunflower oil2.79\[[@CR117]\]*Thermus* sp. CCM 42120.2% (w/v) sunflower oil2.12\[[@CR117]\]*Meiothermus ruber* CCM 28420.2% (w/v) sunflower oil1.505\[[@CR117]\]The non-reported yield is labeled as NA

Rhamnolipid synthesis and regulation in *P. aeruginosa* {#Sec5}
=======================================================

*Pseudomonas aeruginosa* has been used as the model strain to understand the genes that are critical for rhamnolipid biosynthesis. Production of rhamnolipids in *Pseudomonas* involves several steps. The precursors for rhamnolipid synthesis are the sugar (dTDP-[l]{.smallcaps}-rhamnose) and hydrophobic moieties such as 3-(3-hydroxyalkanoyloxy)alkanoic acid (HAA). The sugar moiety can be synthesized from [d]{.smallcaps}-glucose, while the hydrophobic moiety can be synthesized through the fatty acid synthesis pathway, starting with two-carbon units \[[@CR16]\]. Most bacteria contain the required enzymes for synthesizing the precursors in rhamnolipid biosynthesis but the enzymes involved in the synthesis of HAA, mono- and di-rhamnolipids are found almost exclusively in *Pseudomonas* sp. and *Burkholderia* sp. (Fig. [1](#Fig1){ref-type="fig"}). Synthesis of rhamnolipids and their precursors only occurs upon induction of the related gene products to express the key enzymes for the rhamnolipid biosynthesis pathway.

Quorum sensing system {#Sec6}
---------------------

Bacterial quorum sensing (QS) is bacterial communication system where signal molecules known as auto-inducers are secreted to generate coordinated behaviors within a bacterial population. The QS system consists of a signal synthase, a signal receptor protein and a signal molecule in many gram-negative bacteria \[[@CR4]\]. In *P. aeruginosa*, there are three QS systems including *las*, *rhl* and *pqs* systems that are responsible for regulating rhamnolipid production \[[@CR4], [@CR6], [@CR17]--[@CR19]\]. The LasI and RhlI synthases produce corresponding signal molecules, homoserine lactones 3OC~12~-HSL and C~4~-HSL, which bind and modulate LasR and RhlR modulators, respectively. RsaL can affect rhamnolipid biosynthesis by suppressing both LasI and LasR \[[@CR4]\]. The *rhl* system directly controls the biosynthesis of rhamnolipids through the transcription factor RhlR \[[@CR20]\] and its autoinducer C~4~-HSL. C~4~-HSL forms a complex with RhlR to activate the transcription of *rhlAB* genes to initiate rhamnolipid biosynthesis during stationary phase \[[@CR20]--[@CR22]\]. It has been shown that 1 µM RhlI or 10% of cell-free supernatant is sufficient for full induction of rhamnolipid biosynthesis, which usually starts 3 h after induction. However, the maximal production of rhamnolipids only occurred 20--36 h after induction \[[@CR20]\]. In contrast, exogenous addition of C~4~-HSL to the culture medium is not helpful for initiating the expression of *rhlAB* during exponential phase, which implies that additional regulatory elements are present to prevent the initiation of rhamnolipid biosynthesis before the onset of stationary phase \[[@CR23]\]. Although the addition of exogenous auto-inducer did not boost rhamnolipid production, it was found that the presence of 20% spent medium helped to increase rhamnolipid yield by 9.39%, which might be due to the presence of endogenous auto-inducer in the spent medium \[[@CR24]\]. One of the functions of rhamnolipids is to increase the bioavailability of hydrocarbon substrate as carbon source \[[@CR15]\]. Hence, the synthesis of rhamnolipids can also be induced by the presence of water-insoluble substrates in the fermentation medium such as hydrocarbons \[[@CR25], [@CR26]\], which has been used as a strategy to improve rhamnolipid production.

Key enzymes in rhamnolipid synthesis {#Sec7}
------------------------------------

The lipid moiety of rhamnolipid is synthesized by the classical type-II fatty acid synthase (FAS II) which exists in most bacteria. The formation of the precursor HAA that constitute the hydrophobic portion of rhamnolipids is catalyzed by RhlA, using β-hydroxydecanoyl-ACP from the fatty acid synthesis pathway as the substrate. Rhamnose can be found in the lipopolysaccharide (LPS) component of cell wall in *Pseudomonas* species and O-antigen polysaccharides of some gram-negative bacteria. The precursor dTDP-L-rhamnose for rhamnolipid biosynthesis is synthesized from [d]{.smallcaps}-glucose-1-phosphate, which can be obtained from both gluconeogenesis and Entner--Doudoroff pathways utilizing [d]{.smallcaps}-glucose as the starting molecule \[[@CR4]\]. Phosphoglucomutase AlgC and gene products of *rmlBDAC* operon are essential for producing dTDP-[l]{.smallcaps}-rhamnose from [d]{.smallcaps}-glucose-1-phosphate \[[@CR27]\]. Most of the enzymes involving in rhamnolipid biosynthesis are present in many bacteria except for the three key enzymes RhlA, RhlB and RhlC.

As aforementioned, RhlA catalyzes formation of HAA---the hydrophobic precursor of rhamnolipids. RhlB is a rhamnosyltransferase that is capable of catalyzing the reaction between HAA and dTDP-[l]{.smallcaps}-rhamnose to form mono-rhamnolipid. RhlA and RhlB are encoded by the *rhlAB* operon that is tightly controlled by the QS systems (Fig. [1](#Fig1){ref-type="fig"}). RhlC, encoded by the *rhlC*, is a rhamnosyltransferase II that is responsible for production of di-rhamnolipids using mono-rhamnolipid and another dTDP-[l]{.smallcaps}-rhamnose as substrates. RhlA, RhlB and RhlC, which are important enzymes to control the production of rhamnolipids, are found almost exclusively in *Pseudomonas* sp. and *Burkholderia* sp. Theoretically, non-pathogenic strains will be able to produce rhamnolipids when these three genes are introduced. The population of mono- and di-rhamnolipids can also be altered by varying the expression levels of RhlB and RhlC. Indeed, many studies have been carried out to obtain rhamnolipid-producing strains through metabolic engineering \[[@CR4]\]. The recombinant bacteria harboring these genes are able to produce rhamnolipids (see below).

Challenges in microbial production of rhamnolipids {#Sec8}
==================================================

Several laboratory studies have proven the possibility of producing rhamnolipids in pilot scale, and companies such as Evonik are known to have spent efforts in exploring large scale production of rhamnolipids for commercialization \[[@CR28], [@CR29]\]. Despite these progresses, production of biosurfactants by microbial fermentation can only replace synthetic surfactants when the cost of raw materials and process is reduced \[[@CR29]\]. The high cost for rhamnolipid production is mainly due to fermentation and product purification steps. The cost of synthetic surfactants is \$1--3/kg, whereas rhamnolipids cost \$20--25/kg depending on the volumetric productivity of rhamnolipid fermentation \[[@CR30], [@CR31]\]. Due to higher production cost in fermentation, it is difficult for rhamnolipids to compete with synthetic surfactants economically. Microbial fermentation to produce rhamnolipids is only economically viable when rhamnolipids are required in the manufacturing of high-priced products such as cosmetics and medicines \[[@CR32]\]. Nonetheless, as the demand for surfactants is increasing annually, it is still important to explore strategies to reduce the cost for rhamnolipids production \[[@CR30]\].

The costs involved in rhamnolipid production originate from the raw materials to serve as carbon and nitrogen sources for the microorganism, the fermentation procedures and the downstream processes (Fig. [2](#Fig2){ref-type="fig"}). The cost for carbon source is high because hydrophobic substrates are usually used to achieve high product yield, and such substrates are normally more expensive than sugar-based substrates. The cost of raw materials for rhamnolipid fermentation was estimated to be 50% of the total production cost \[[@CR30]\]. Fermentation strategy is also important for saving operation cost and increasing the product titers. Quite a few studies have shown that fermentation conditions affect the rhamnolipid yield dramatically. Purification of rhamnolipid is a complicated step because of the complexity of the fermentation products consisting of proteins, lipids, small molecules and others. Extensive purification steps are required to obtain pure product, which not only require time but also additional operation and reagent expenses. Furthermore, other than optimizing the fermentation and purification strategy, choosing a competent strain for fermentation is also a critical element to reduce production cost because the yields of rhamnolipids vary from species to species.Fig. 2A flow chart of rhamnolipids production. This flow chart shows the procedures for rhamnolipid production. A large scale rhamnolipid production contains the following steps: seed preparation, fermentation, production purification. For a given strain, the costs are focused on the fermentation and purification steps. Seed preparation for fermentation is a common step which does not require extra cost. Fermentation cost includes carbon and nitrogen sources, fermentation styles, and other additional steps or chemicals required for rhamnolipid production. Cost for production purification depends on the required production purity. Some applications may not require rhamnolipid purification

Strategies to reduce production cost {#Sec9}
====================================

One strategy to reduce the overall rhamnolipid production cost is to lower fermentation (including selection of a suitable strain and an optimized fermentation process) and purification cost (Fig. [3](#Fig3){ref-type="fig"}). For example, economic carbon sources such as wastes and renewable substrates \[[@CR3]\] can be used to replace some conventional substrates. These include mannitol \[[@CR33]\], glucose, glycerol, *n*-paraffin \[[@CR34], [@CR35]\], *n*-alkane, polycyclic aromatic hydrocarbons \[[@CR36]\] and vegetable oils \[[@CR37]\]. The diversity of renewable resources that can be used as carbon and nitrogen sources for rhamnolipid fermentation with reduced substrate cost are discussed in detail in several recent reviews \[[@CR3], [@CR38]--[@CR40]\]. The rhamnolipid yield is largely dependent on the choice of the rhamnolipid producer, the medium composition and the fermentation conditions \[[@CR32]\] as the titers of rhamnolipids ranged from 3.9 to 78.56 g/l depending on the cultivation strategies proposed in the literature. The highest titer ever reported was 112 g/l achieved from *P. aeruginosa* fermentation using soybean oil as carbon source in N-limited and Ca^2+^-free medium at 30 °C, pH 6.3 \[[@CR31], [@CR41], [@CR42]\].Fig. 3Strategies to reduce rhamnolipid production cost. **a** Strain screening. A good strain can reduce the production cost effectively; **b** strain modification by mutagenesis and metabolic engineering; **c** fermentation. Fermentation is an important step which requires a lot of efforts to optimize. The possible factors that affect fermentation cost are listed

Downstream processing in many biotechnological processes can contribute up to 50--80% of the total production cost \[[@CR26], [@CR43]\] depending on the difficulty of product recovery, which is based on the ionic charge, water solubility and location of the product (intracellular, extracellular or bounded to cell membrane). As rhamnolipids are recovered from fermentation broth, a complex mixture containing unfermented substrates, salts, amino acids, proteins and other metabolic products, downstream purification of rhamnolipids is difficult especially for low rhamnolipid titers \[[@CR44]\]. Despite such complexities, it is still possible to purify rhamnolipids with relatively high purity using various proposed strategies such as foam fractionation \[[@CR44]\]. The product purification cost can be significantly lowered if (1) cell-free fermentation broth to be used in place of purified rhamnolipids for industrial applications such as in oil recovery or (2) direct usage of rhamnolipid-producing microorganisms applications such as cleaning of oil contamination and additive for animal feeds.

Application of various strategies to increase rhamnolipid yield {#Sec10}
===============================================================

Obtaining a strain with high rhamnolipid yield is the most important step to save production cost, as less complicated purification procedures will be needed. The most commonly used strategy to obtain good strains is to isolate them from the environments where biosurfactant-producing strains can be enriched. Extensive screening has been carried out by many laboratories to isolate and identify various rhamnolipid-producing strains (Table [2](#Tab2){ref-type="table"}). It has been noted that the rhamnolipid yields of *P. aeruginosa* strains remain the highest among the bacteria studied. There are also extensive studies identifying the genes that are critical for rhamnolipid production such that metabolic engineering approach can be used to obtain potential yet safe rhamnolipid-producing strains.

Improving rhamnolipid yield through random mutagenesis {#Sec11}
------------------------------------------------------

Mutagenesis through chemical or radiation treatment can be used to improve rhamnolipid yield. For example, a *P. aeruginosa* EBN-8 mutant was obtained by mutagenesis using gamma radiation and was shown to have a better growth on oil refinery wastes than the wild type by producing 8.5 g/l rhamnolipids \[[@CR45]\]. *P. fluorescens* 29L obtained under UV mutagenesis was able to produce mutants that were capable of growing on pyrene \[[@CR46]\]. Mutagenesis of *P. aeruginosa* by using chemical mutagen *N*-methyl-*N*'-nitro-*N*-nitrosoguanidine (MNNG) generated a mutant which produced 70--120 g/l rhamnolipids \[[@CR42]\]. Another study employed UV mutagenesis on rhamnolipid producers from the soil samples generated a mutant with two-fold increment in rhamnolipid production over the parent strain \[[@CR4]\]. The random mutagenesis method has been widely used to improve microbial production, but the mutants may lose its productivity after some time.

Metabolic engineering for non-pathogenic strains {#Sec12}
------------------------------------------------

Rhamnolipid biosynthesis in *P. aeruginosa* requires the precursors HAA and dTDP-[l]{.smallcaps}-rhamnose, where HAA is synthesized from β-hydroxydecanoyl-ACP. As the biosynthesis pathway for both β-hydroxydecanoyl-ACP and dTDP-[l]{.smallcaps}-rhamnose are present in many bacteria, it is therefore possible to construct non-pathogenic recombinant strains by introducing the genes important for rhamnolipid biosynthesis through metabolic engineering tools. HAA is produced in the presence of RhlA, whereas introduction of *rhlB* into the recombinant strain produces mono-rhamnolipid. The heterologous expression of *rhlA*, *rhlB* and *rhlC* will allow the host strain to produce both mono- and di-rhamnolipids. Recombinant strains can produce predominantly di-rhamnolipid if more copies of *rhlC* are expressed in the host strains.

It had been shown that a simple increment in the copy number of *rhlAB* under the control of indigenous strong promoter of *oprL* in *P. aeruginosa* SG could raise the rhamnolipid titer to 20.98 g/l \[[@CR47]\]. Similarly, the overexpression of *rhlAB* under *tac* promoter in *B. kururiensis* increased the rhamnolipid titer from 0.78 to 5.76 g/l \[[@CR48]\]. The recombinant *B. kururiensis* produces more than 50 rhamnolipid homologues which are typical of both *Pseudomonas* sp. and *Burkholderia* sp., implying that the metabolic engineering can also provide a means in modifying the composition and types of rhamnolipid congeners produced to alter the physicochemical properties of the rhamnolipids \[[@CR48]\]. Likewise, *P. chlororaphis,* which was previously reported to produce only mono-rhamnolipids, was shown to be able to produce di-rhamnolipids by overexpressing *rhlC* under a constitutive promoter \[[@CR49]\]. The rhamnolipid composition was also altered by site-directed mutagenesis on *rhlB* that resulted in the modification to the volume of the substrate binding pocket \[[@CR50]\]. The *rhlAB* operon was also introduced into several other non-pathogenic bacteria, some of which were unable to produce rhamnolipids naturally, such as *E. coli* \[[@CR50]--[@CR52]\], *P. putida* \[[@CR53], [@CR54]\], *P. stutzeri* \[[@CR55]\] and *P. fluorescens* \[[@CR54]\], to enhance rhamnolipid yields. Interestingly, Cabrera-Valladares et al. \[[@CR52]\] reported that co-expression of *rmlBDAC* with *rhlAB* was required for rhamnolipid production since dTDP-L-rhamnose was limited in *E. coli*, but the later study suggested that *rmlBDAC* might not be required for rhamnolipid production \[[@CR51]\]. The overexpression of *rhlAB* and *rhlRI* from *P. aeruginosa* EMS1 in *P. putida* KCTC produced 7.3 g/l of rhamnolipids \[[@CR56]\]. *P. putida* KT2440, capable of growing at high concentrations of rhamnolipids, is reported to be a safe strain for microbial production. By introducing *rhlAB* from *P. aeruginosa,* the recombinant *P. putida* KT2440 was able to produce mono-rhamnolipid. Further deletion of the polyhydroxyalkanoate formation related gene, *phaC,* in *P. putida,* aided in an improvement of the rhamnolipid yield to 1.5 g/g glucose \[[@CR53]\]. By replacing the native promoter of *rhlAB* with a synthetic promoter on plasmid pSynPro8oT-rhlAB, heterologous production in recombinant *P. putida* KT2440 using fed-batch fermentation could reach 14.9 g/l when combined with two-phase glucose feeding strategy \[[@CR57]\]. All these studies clearly demonstrate the possibility of producing rhamnolipids using non-pathogenic strains.

Metabolic engineering of *P. aeruginosa* to increase yield {#Sec13}
----------------------------------------------------------

A metabolic engineering approach to enhance rhamnolipid yield in *P. aeruginosa* is either through introducing genes that promote rhamnolipid production or deleting genes that inhibit rhamnolipid biosynthesis. The regulation of rhamnolipid biosynthesis is complicated, further increasing the difficulty to improve rhamnolipid yield via metabolic engineering approaches. Catabolite repression control (Crc) protein is able to activate QS to affect rhamnolipid production through down-regulation of Lon protease. This protease can degrade RhlI protein both in vivo and in vitro. Deletion of the *crc* gene reduces the production of rhamnolipids in *P. aeruginosa*. On the other hand, deletion of *clpX* or *lon* can increase the production of rhamnolipids as they are negative regulators of QS in *P. aeruginosa* \[[@CR58]\]. The outer membrane protein EstA affects the production of rhamnolipid in *P. aeruginosa* through its esterase domain. Overexpression of EstA in *P. aeruginosa* results in higher rhamnolipid production than the wild type strain \[[@CR59]\]. Hemoglobin from *Vitreoscilla* is useful for increasing oxygen transfer in bacteria, and expression of this gene in *P. aeruginosa* NRRL B-771 increased the titer of rhamnolipids to 8.4 or 13.3 g/L depending on the fermentation media used \[[@CR60]\]. Additionally, metabolic engineering can be employed to widen the range of substrates that can be utilized by host microorganisms. For instance, *lacZY* from *E. coli* was cloned into *P. aeruginosa* PAO1 and PG201, enabling the recombinant strains to be able to utilize lactose present in whey waste \[[@CR61]\].

Synthesis of rhamnolipids in vitro {#Sec14}
----------------------------------

Experimental evidence has shown that purified RhlA is able to catalyze synthesis of HAA in vitro \[[@CR62]\]. Both RhlA and RhlB can be purified from *E. coli* \[[@CR63]\], making it possible to synthesize rhamnolipids in vitro when both the precursors and enzymes are present. Although some concerns such as catalysis efficiency still remain, it is a simple and promising method to obtain rhamnolipids. Other advantages of in vitro rhamnolipid synthesis include easier downstream purification procedures, as well as elimination of pathogenic effect by obtaining the precursors HAA and dTDP-[l]{.smallcaps}-rhamnose from non-pathogenic strains. It is worthwhile to spend efforts on in vitro rhamnolipid synthesis as both mono- and di-rhamnolipids can be obtained using this strategy. However, the expression and purification of RhlC may be challenging using *E. coli* as the host strain \[[@CR63]\]. Nevertheless, non-purified RhlC may still be used for in vitro rhamnolipid synthesis.

Process optimization {#Sec15}
--------------------

Several studies had focused on exploring various fermentation strategies for enhancing rhamnolipid yield by optimization of the fermentation parameters. Currently, many of the proposed methods target on optimization of the components in the growth medium using optimization techniques such as response surface methodology \[[@CR64]\]. However, fermentation parameters including the type and feeding profile of substrates, pH, temperature, aeration rate, dissolved oxygen, cell density and availability of in situ product removal, are essential prerequisites for setting up efficient fermentation strategy as these parameters can significantly impact on the rhamnolipid yield \[[@CR29], [@CR65]\]. For instance, the use of water-insoluble carbon sources such as palm oil and diesel generally produce rhamnolipids in higher titers as compared to water-soluble carbon sources (e.g. glucose) \[[@CR29], [@CR66]\]. The feeding profile of substrates, especially the carbon source, is also an important parameter as fed-batch cultivation is found to be the more effective than batch cultivation to obtain high rhamnolipid titers \[[@CR57], [@CR65]--[@CR67]\]. The key to fed-batch cultivation is to control the substrate concentration at a minimal level that allows optimal microbial growth without catabolite repression or substrate inhibition, and most substrates are utilized for rhamnolipid formation rather than biomass formation. Therefore, kinetic models for substrate utilization, product formation and microbial growth will be useful in developing fed-batch fermentation strategies to dramatically improve the rhamnolipid yield, as evident in several studies \[[@CR64], [@CR67], [@CR68]\]. Controlling pH during fermentation also helps in achieving higher rhamnolipid production. Neutral or slightly alkaline pH (pH 7--7.5) allows optimal microbial growth during initial phase of fermentation, after which slightly acidic pH (pH 6--6.5) maximizes rhamnolipid production by suppressing cell growth in middle and late stages of fermentation. In a study conducted by Zhu et al. \[[@CR65]\], the rhamnolipid yield was increased from 24.06 to 28.8 g/l simply by controlling the pH during batch fermentation, which was further increased to 70.56 g/l using pH-controlled fed-batch fermentation. The aeration rate to control dissolved oxygen level is also an important fermentation parameter since higher rhamnolipid production is attained with higher dissolved oxygen level \[[@CR60], [@CR65]\]. Furthermore, when bioreactors are coupled with tandem defoaming system, in situ product removal helps to prevent product inhibition to enable higher rhamnolipid titers to be reached with other benefits such as obtaining rhamnolipid of high purity with lower purification cost and prevent overflowing of microbial cultures during fermentation \[[@CR29], [@CR68]\].

Reducing the pathogenic impact of *P. aeruginosa* through metabolic engineering {#Sec16}
===============================================================================

The use of *P. aeruginosa* in rhamnolipid production might be restricted due to its potential pathogenicity, although it is still the most important strain to many researchers and industries because of its high yield of rhamnolipid production. It would be very useful if the pathogenicity of this strain can be diminished through metabolic engineering approach. Pyocyanin is one of the secondary metabolites of *P. aeruginosa*. It is a blue redox-active compound and interferes with multiple cellular functions of human beings \[[@CR69]\]. Accumulated studies have shown that pyocyanin, which structure makes it easy to penetrate the cell membrane, is critical for *P. aeruginosa* infection \[[@CR70]\]. Synthesis of pyocyanin is through complex cascade of reactions involving several genes such as *phzABCDEFG* and *phzHMS*. The synthesis of pyocyanin is also regulated by the QS systems \[[@CR71]\]. Inhibition of pyocyanin biosynthesis is considered as a strategy to rid its toxic impact \[[@CR70]\], as well as inhibiting the synthesis of its precursors from the shikimic acid biosynthetic pathway to prevent the expression of the two *phz* operons.

A recent study had characterized a pyocyanin demethylase (PodA) that can oxidize the methyl group of pyocyanin to formaldehyde \[[@CR72]\]. PodA is also able to reduce the pyrazine ring through an unusual tautomerizing demethylation reaction, generating products that may be harmless to human cells. It has been shown that treatment of pyocyanin with PodA is able to disrupt *P. aeruginosa* biofilm formation---the critical step for pathogenesis of *P. aeruginosa*. Such a study provides insight into removing the toxic effect pyocyanin through an enzymatic reaction. Introduction of such enzyme into *P. aeruginosa* might provide an efficient way to eradicate the pathogenicity of *P. aeruginosa* where the recombinant strains will have a great potential in industrial applications. Moreover, purified PodA might be used in *P. aeruginosa* fermentation to remove pyocyanin from the broth. Further studies on this topic will be useful to expand the applications of rhamnolipids produced by *P. aeruginosa* to other areas where pathogenicity of *P. aeruginosa* is a concern.

Concluding remarks {#Sec17}
==================

An excellent rhamnolipid-producing strain is critical for cost-effective production of rhamnolipids. Therefore, various efforts have been making to obtain non-pathogenic strains with high rhamnolipid productivity, which include the isolation of potential rhamnolipid-producing strains from the environment, optimization of fermentation conditions and strain improvement by various mutagenesis and metabolic engineering strategies. Metabolic pathway engineering has become an important strategy in this field with the accumulation of knowledge on rhamnolipid biosynthesis and pathogenesis in *P. aeruginosa*. Metabolic engineering can be applied either for reducing the pathogenicity of *P. aeruginosa* or for constructing excellent non-pathogenic rhamnolipid producers, which are two crucial features for economical and safe production of rhamnolipids. Although the cost of product purification is still high, rhamnolipids in high purity can be obtained at an acceptable cost with carefully-designed strategies for various applications especially for those with high-value products such as cosmetics and medicines.
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